Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Sr.VP & Chief Business Officer | April 13, 2018 | April 17, 2018 |
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Chief Operating Officer | June 08, 2022 | June 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date April 13, 2018 · Filed April 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,788 |
Reported balance
After 2018-04-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-04-13 · Exercise / conversion · Acquired 8,163 · Balance 22,788 |
| Common StockSEC Table I · non-derivative | Direct | 14,625 |
Reported balance
After 2018-04-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-04-13 · Sale · Disposed 8,163 · Balance 14,625 F1: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. F2: Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.07 · Expires 2024-12-10 | Direct | 3,750 |
Reported balance
After 2018-04-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-13 · Exercise / conversion · Disposed 8,163 · Balance 3,750 F3: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
F2: Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
F3: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
Senti Biosciences Holdings, Inc.
Report date June 08, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 454,208 |
Reported balance
Holding disclosure · report date 2022-06-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 454,208 F1: The shares are held by the C. and E. Herberts Revocable Trust dated July 17, 2013 ("Herberts Trust"), over which the reporting person and his wife share voting and investment power as trustees. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.92 · Expires 2031-12-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of the shares underlying this option vest on June 8, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date. |
| Earnout Rights (Common Stock)SEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Each earnout right represents a contingent right to receive one share of the Issuer's Common Stock. The earnout rights vest, if on or before the date which is two (2) calendar years after June 8, 2022, the volume weighted average price of shares of the Issuer's Common Stock ("VWAP"), is greater than or equal to fifteen dollars ($15.00) over any twenty (20) trading days within any consecutive thirty (30) trading day period. If the target VWAP is not achieved during such period, the earnout rights will be forfeited. F1: The shares are held by the C. and E. Herberts Revocable Trust dated July 17, 2013 ("Herberts Trust"), over which the reporting person and his wife share voting and investment power as trustees. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
| Earnout Rights (Common Stock)SEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2022-06-08 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Each earnout right represents a contingent right to receive one share of the Issuer's Common Stock. The earnout rights vest, if on or before the date which is three (3) calendar years after June 8, 2022, the VWAP is greater than or equal to twenty dollars ($20.00) over any twenty (20) trading days within any consecutive thirty (30) trading day period. If the target VWAP is not achieved during such period, the earnout rights will be forfeited. F1: The shares are held by the C. and E. Herberts Revocable Trust dated July 17, 2013 ("Herberts Trust"), over which the reporting person and his wife share voting and investment power as trustees. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by the C. and E. Herberts Revocable Trust dated July 17, 2013 ("Herberts Trust"), over which the reporting person and his wife share voting and investment power as trustees. The reporting person disclaims Section 16 beneficial ownership of the securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
F2: 25% of the shares underlying this option vest on June 8, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.
F3: Each earnout right represents a contingent right to receive one share of the Issuer's Common Stock. The earnout rights vest, if on or before the date which is two (2) calendar years after June 8, 2022, the volume weighted average price of shares of the Issuer's Common Stock ("VWAP"), is greater than or equal to fifteen dollars ($15.00) over any twenty (20) trading days within any consecutive thirty (30) trading day period. If the target VWAP is not achieved during such period, the earnout rights will be forfeited.
F4: Each earnout right represents a contingent right to receive one share of the Issuer's Common Stock. The earnout rights vest, if on or before the date which is three (3) calendar years after June 8, 2022, the VWAP is greater than or equal to twenty dollars ($20.00) over any twenty (20) trading days within any consecutive thirty (30) trading day period. If the target VWAP is not achieved during such period, the earnout rights will be forfeited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2017 Filed Dec 5, 2017 00:39 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 13,433 | $9.41 | $126,404.53 |
DisclosureSEC source: 0001209191-17-063672 · doc4.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,000 shares acquired by the Reporting Person on October 31, 2017 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,754 | $0.00 Strike: $9.41 | $0.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · derivative · entry 9 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,746 Underlying: Common Stock · 3,754 shares Expires 2025-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-quarter (1/4) of the option shares will vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,416 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · derivative · entry 8 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Underlying: Common Stock · 5,416 shares Expires 2025-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,830 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · derivative · entry 7 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,830 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 3,754 | $16.00 | $60,064.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 6 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 3,754 | $9.41 | $35,325.14 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 5 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,416 | $15.00 | $81,240.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 4 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,416 | $8.87 | $48,039.92 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 3 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,830 | $15.00 | $87,450.00 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 2 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:22 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,830 | $5.41 | $31,540.30 |
DisclosureSEC source: 0001209191-17-055830 · doc4.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,316 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001209191-17-051084 · doc4.xml · derivative · entry 4 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,830 Underlying: Common Stock · 10,316 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 10,316 | $15.00 | $154,740.00 |
DisclosureSEC source: 0001209191-17-051084 · doc4.xml · nonDerivative · entry 3 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 10,316 | $5.41 | $55,809.56 |
DisclosureSEC source: 0001209191-17-051084 · doc4.xml · nonDerivative · entry 2 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 22:19 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 4,684 | $15.00 | $70,260.00 |
DisclosureSEC source: 0001209191-17-051084 · doc4.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,833 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · derivative · entry 8 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 5,000 | $11.00 | $55,000.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · nonDerivative · entry 5 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $5.12 | $25,600.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · nonDerivative · entry 4 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · derivative · entry 7 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2021-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,474 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · derivative · entry 6 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,474 shares Expires 2020-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 6,474 | $10.00 | $64,740.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · nonDerivative · entry 3 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 3,000 | $2.55 | $7,650.00 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · nonDerivative · entry 2 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:31 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 3,474 | $3.99 | $13,861.26 |
DisclosureSEC source: 0001209191-17-049038 · doc4.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2017 Filed Jul 15, 2017 00:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 172 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-17-045272 · doc4.xml · derivative · entry 4 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,474 Underlying: Common Stock · 172 shares Expires 2020-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option are fully vested and exercisable. Read SEC document |
| July 14, 2017 Filed Jul 15, 2017 00:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 14,828 | $10.00 | $148,280.00 |
DisclosureSEC source: 0001209191-17-045272 · doc4.xml · nonDerivative · entry 3 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| July 14, 2017 Filed Jul 15, 2017 00:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 172 | $10.00 | $1,720.00 |
DisclosureSEC source: 0001209191-17-045272 · doc4.xml · nonDerivative · entry 2 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,345 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. Read SEC document |
| July 14, 2017 Filed Jul 15, 2017 00:06 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 172 | $3.99 | $686.28 |
DisclosureSEC source: 0001209191-17-045272 · doc4.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Sr.VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2017 Filed Jun 3, 2017 00:26 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 2,000 | $6.80 | $13,600.00 |
DisclosureSEC source: 0001140361-17-023684 · doc1.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Senior VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,345 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. F2 · balance_after: Includes 3,333 and 12,500 shares subject to restricted stock units (RSUs) granted on December 11, 2014 and December 8, 2015, respectively, that will be issued as such units vest in accordance with their terms. Read SEC document |
| May 12, 2017 Filed May 15, 2017 23:42 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 2,000 | $8.50 | $17,000.00 |
DisclosureSEC source: 0001140361-17-020870 · doc1.xml · nonDerivative · entry 2 Herberts Curt A. III · CIK 0001691262 · Senior VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,345 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on April, 30, 2017 under the Issuer's Employee Stock Purchase Plan. F3 · balance_after: Includes 3,333 and 12,500 shares subject to restricted stock units (RSUs) granted on December 11, 2014 and December 8, 2015, respectively, that will be issued as such units vest in accordance with their terms. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:42 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 639 | $6.50 | $4,153.50 |
DisclosureSEC source: 0001140361-17-020870 · doc1.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Senior VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,345 F1 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person on April, 30, 2017 under the Issuer's Employee Stock Purchase Plan. F3 · balance_after: Includes 3,333 and 12,500 shares subject to restricted stock units (RSUs) granted on December 11, 2014 and December 8, 2015, respectively, that will be issued as such units vest in accordance with their terms. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 21:55 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001140361-17-003488 · doc1.xml · derivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Senior VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter. Read SEC document |
| December 12, 2016 Filed Dec 15, 2016 01:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 4,852 | $3.05 | $14,798.60 |
DisclosureSEC source: 0001140361-16-089716 · doc1.xml · nonDerivative · entry 1 Herberts Curt A. III · CIK 0001691262 · Senior VP & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 F1 · shares: Represents shares withheld to satisfy the Reporting Person's tax withholding obligation upon the vesting and issuance of RSUs. F2 · ownership.direct: Includes 3,333 and 12,500 shares subject to RSUs granted on December 11, 2014 and December 8, 2015 respectively, that will be issued as such units vest in accordance with their terms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.